Combination therapy

US8709419B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Kapil Dhingra · Tenafly, US
• Brian Higgins · Dayton, US
• Kenneth Kolinsky · Bloomingdale, US
• Richard J. Lee · Montclair, US
• Brian Lestini · Union City, US
• Kathryn Packman · Newton, US
• Fei Su · Wang'an Town, TW

Key dates

• Filing date: Aug 10, 2011
• Grant date: Apr 29, 2014
• Expiry date: Mar 25, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to a combination therapy of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for treating a patient suffering from a proliferative disorder, in particular a solid tumor, for example, colorectal cancer, melanoma, and thyroid cancer.